Savara’s (SVRA) Market Outperform Rating Reaffirmed at JMP Securities

Savara (NASDAQ:SVRA)‘s stock had its “market outperform” rating restated by research analysts at JMP Securities in a report released on Monday, Benzinga reports. They presently have a $8.00 price target on the stock. JMP Securities’ price objective would indicate a potential upside of 52.09% from the company’s previous close.

Separately, Piper Sandler raised their target price on Savara from $7.00 to $16.00 and gave the stock an “overweight” rating in a research report on Monday, March 4th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $8.20.

Savara Trading Up 6.3 %

NASDAQ:SVRA opened at $5.26 on Monday. Savara has a 12-month low of $1.83 and a 12-month high of $5.70. The firm has a market cap of $726.83 million, a PE ratio of -15.94 and a beta of 0.73. The company has a current ratio of 15.66, a quick ratio of 15.66 and a debt-to-equity ratio of 0.19. The stock has a fifty day moving average price of $4.89 and a 200 day moving average price of $4.51.

Savara (NASDAQ:SVRA) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.02. Sell-side analysts anticipate that Savara will post -0.38 earnings per share for the current fiscal year.

Institutional Trading of Savara

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AJOVista LLC purchased a new stake in shares of Savara during the fourth quarter worth approximately $40,000. Principal Financial Group Inc. purchased a new position in Savara during the 3rd quarter worth $48,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Savara in the 4th quarter worth $74,000. Kestra Private Wealth Services LLC purchased a new stake in shares of Savara in the third quarter valued at about $64,000. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Savara by 665.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 19,507 shares of the company’s stock valued at $92,000 after acquiring an additional 16,959 shares in the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.